Stomatological Hospital, Southern Medical University, Guangzhou, China.
Department of General Surgery, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Front Immunol. 2023 Feb 6;14:1087755. doi: 10.3389/fimmu.2023.1087755. eCollection 2023.
Digestive tract-related cancers account for four of the top ten high-risk cancers worldwide. In recent years, cancer immunotherapy, which exploits the innate immune system to attack tumors, has led to a paradigm shifts in cancer treatment. Gut microbiota modification has been widely used to regulate cancer immunotherapy. Dietary compounds and traditional Chinese medicine (TCM) can alter the gut microbiota and its influence on toxic metabolite production, such as the effect of iprindole on lipopolysaccharide (LPS), and involvement in various metabolic pathways that are closely associated with immune reactions. Therefore, it is an effective strategy to explore new immunotherapies for gastrointestinal cancer to clarify the immunoregulatory effects of different dietary compounds/TCMs on intestinal microbiota. In this review, we have summarized recent progress regarding the effects of dietary compounds/TCMs on gut microbiota and their metabolites, as well as the relationship between digestive cancer immunotherapy and gut microbiota. We hope that this review will act as reference, providing a theoretical basis for the clinical immunotherapy of digestive cancer gut microbiota modulation.
消化道相关癌症占全球十大高危癌症中的四项。近年来，利用先天免疫系统攻击肿瘤的癌症免疫疗法在癌症治疗方面带来了范式转变。肠道微生物群修饰已被广泛用于调节癌症免疫疗法。膳食化合物和中药（TCM）可以改变肠道微生物群及其对毒性代谢产物产生的影响，例如吲达胺对脂多糖（LPS）的影响，并参与与免疫反应密切相关的各种代谢途径。因此，探索胃肠道癌症的新免疫疗法以阐明不同膳食化合物/TCM 对肠道微生物群的免疫调节作用是一种有效的策略。在这篇综述中，我们总结了膳食化合物/TCM 对肠道微生物群及其代谢物的影响，以及消化癌症免疫疗法与肠道微生物群之间的关系。我们希望这篇综述能为消化癌症的临床免疫治疗和肠道微生物群调节提供参考，提供理论基础。
